MacroGenics (MGNX)
(Delayed Data from NSDQ)
$3.00 USD
-0.06 (-1.96%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $3.00 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
MacroGenics, Inc. [MGNX]
Reports for Purchase
Showing records 301 - 320 ( 364 total )
Company: MacroGenics, Inc.
Industry: Medical - Products
MGNX''s Third DART Candidate Advances to Clinic for Treatment of Autoimmune Disorders
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
Q4:14 EPS; on Track for Multiple Trial Initiations for 2015; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
Well Positioned and Expanding Pipeline Supported by Cash till 2018
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events from the Week of March 2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: MacroGenics, Inc.
Industry: Medical - Products
Biotechnology/Biopharma: 27th Annual ROTH Conference: Healthcare Track Preview
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
Setting Up For An Eventful 2H15, Buy The Dips
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
Upcoming Investors Meeting Setting The Tone For A Data Rich Year
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY.
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
Valuation Gap Between Bi-specifics And CAR T''s Likely To Narrow
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
J-J Licenses MGD011 and Takes Equity Stake, Attractive Terms Further Validate DART Platform, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
JNJ Collaboration Marks the Start of An Eventful Year Ahead; Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
Anticipating a Breakout 2015, Adding to Focus List, Target to $45
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
Biotechnology/Biopharmaceuticals/BioDefense-Recap of American Society for Hematology Meeting (ASH) 2014 Presentations
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D